{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:11:00Z","timestamp":1789186260748,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.acvd.2024.08.006","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T21:00:26Z","timestamp":1728075626000},"page":"123-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical outcomes for 2788 patients with transthyretin amyloidosis: Tafamidis meglumine early access program in France"],"prefix":"10.1016","volume":"118","author":[{"given":"Olivier","family":"Lairez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"R\u00e9ant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn","family":"Inamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Jeanneteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Eicher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Lequeux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Legallois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constant","family":"Josse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelie","family":"Hippocrate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Bartoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaux","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Noirot Cosson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Alexandre","family":"Squara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Fievez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Quinault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremie","family":"Rudant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mounira","family":"Kharoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaud","family":"Damy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.acvd.2024.08.006_bib0135","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2024.08.006_bib0140","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/13506129.2020.1835263","article-title":"Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee","volume":"27","author":"Benson","year":"2020","journal-title":"Amyloid"},{"key":"10.1016\/j.acvd.2024.08.006_bib0145","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1146\/annurev.med.51.1.543","article-title":"The genetics of the amyloidoses","volume":"51","author":"Buxbaum","year":"2000","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.acvd.2024.08.006_bib0150","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/eurheartj\/ehs123","article-title":"Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective","volume":"34","author":"Rapezzi","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2024.08.006_bib0155","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1002\/ehf2.13652","article-title":"History of extracardiac\/cardiac events in cardiac amyloidosis: prevalence and time from initial onset to diagnosis","volume":"8","author":"Kharoubi","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.acvd.2024.08.006_bib0160","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1016\/j.mayocp.2021.04.021","article-title":"Early diagnosis and outcome in patients with wild-type transthyretin cardiac amyloidosis","volume":"96","author":"Fumagalli","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.acvd.2024.08.006_bib0165","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2024.08.006_bib0170","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/cpdd.789","article-title":"The bioequivalence of tafamidis 61-mg free acid capsules and tafamidis meglumine 4\u00a0\u00d7\u00a020-mg capsules in healthy volunteers","volume":"9","author":"Lockwood","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.acvd.2024.08.006_bib0175","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2024.08.006_bib0180","series-title":"Recommendation for the temporary use of Vyndaquel 20\u00a0mg","year":"2018"},{"key":"10.1016\/j.acvd.2024.08.006_bib0185","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003815","article-title":"Design and rationale of the phase 3 ATTR-ACT clinical trial (tafamidis in transthyretin cardiomyopathy clinical trial)","volume":"10","author":"Maurer","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.acvd.2024.08.006_bib0190","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ejhf.2027","article-title":"Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study","volume":"23","author":"Damy","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.acvd.2024.08.006_bib0195","series-title":"\u00c9pid\u00e9miologie\u00a0: principes et m\u00e9thodes quantitatives","author":"Bouyer","year":"2009"},{"key":"10.1016\/j.acvd.2024.08.006_bib0200","series-title":"National demographics","year":"2023"},{"key":"10.1016\/j.acvd.2024.08.006_bib0205","series-title":"Recommandation temporaire d\u2019utilisation du m\u00e9dicament (RTU) Vyndaqel (tafamidis) dans le traitement de l\u2019amylose cardiaque \u00e0 transthyr\u00e9tine","year":"2018"},{"key":"10.1016\/j.acvd.2024.08.006_bib0210","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3389\/fpubh.2019.00416","article-title":"A review of rare disease policies and orphan drug reimbursement systems in 12 Eurasian countries","volume":"7","author":"Czech","year":"2019","journal-title":"Front Public Health"},{"key":"10.1016\/j.acvd.2024.08.006_bib0215","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.mayocp.2022.08.016","article-title":"Real-life evaluation of an algorithm for the diagnosis of cardiac amyloidosis","volume":"98","author":"Bezard","year":"2023","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.acvd.2024.08.006_bib0220","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.acvd.2023.07.003","article-title":"Changes in amyloidosis phenotype over 11 years in a cardiac amyloidosis referral centre cohort in France","volume":"116","author":"Damy","year":"2023","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2024.08.006_bib0225","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3109\/07853890.2015.1068949","article-title":"Evolving landscape in the management of transthyretin amyloidosis","volume":"47","author":"Hawkins","year":"2015","journal-title":"Ann Med"},{"key":"10.1016\/j.acvd.2024.08.006_bib0230","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/joim.12383","article-title":"Cardiac amyloidosis: where are we today?","volume":"278","author":"Patel","year":"2015","journal-title":"J Intern Med"},{"key":"10.1016\/j.acvd.2024.08.006_bib0235","doi-asserted-by":"crossref","first-page":"100148","DOI":"10.1016\/j.jacadv.2022.100148","article-title":"Improvements in efficacy measures with tafamidis in the tafamidis in transthyretin cardiomyopathy clinical trial","volume":"1","author":"Hanna","year":"2022","journal-title":"JACC Adv"},{"key":"10.1016\/j.acvd.2024.08.006_bib0240","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10214868","article-title":"Prognostic value of N-terminal pro-brain natriuretic peptide and high-sensitivity troponin T levels in the natural history of transthyretin amyloid cardiomyopathy and their evolution after tafamidis treatment","volume":"10","author":"Oghina","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.acvd.2024.08.006_bib0245","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/ehjci\/jeac049","article-title":"Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis","volume":"23","author":"Giblin","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.acvd.2024.08.006_bib0250","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/13506129.2022.2131385","article-title":"Impact of tafamidis on myocardial strain in transthyretin amyloid cardiomyopathy","volume":"30","author":"Rettl","year":"2023","journal-title":"Amyloid"},{"key":"10.1016\/j.acvd.2024.08.006_bib0255","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.jcmg.2022.06.013","article-title":"Tafamidis decreases cardiac uptake of (99m)Tc-HMDP in transthyretin cardiac amyloidosis","volume":"15","author":"Odouard","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.acvd.2024.08.006_bib0260","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/ehjci\/jead030","article-title":"Monitoring tafamidis treatment with quantitative SPECT\/CT in transthyretin amyloid cardiomyopathy","volume":"24","author":"Rettl","year":"2023","journal-title":"Eur Heart J Cardiovasc Imaging"}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213624003231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213624003231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:58:10Z","timestamp":1769907490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875213624003231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1875213624003231"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2024.08.006","relation":{},"ISSN":["1875-2136"],"issn-type":[{"value":"1875-2136","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical outcomes for 2788 patients with transthyretin amyloidosis: Tafamidis meglumine early access program in France","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2024.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}